Mirae Asset Global Investments Co. Ltd. Buys 1,186 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 21,973 shares of the company’s stock after buying an additional 1,186 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Pacira BioSciences were worth $741,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 96.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock worth $36,000 after buying an additional 583 shares during the period. Nisa Investment Advisors LLC raised its holdings in Pacira BioSciences by 310.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company’s stock worth $61,000 after buying an additional 1,514 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Pacira BioSciences by 63.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,481 shares of the company’s stock worth $137,000 after buying an additional 1,736 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 9.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company’s stock worth $157,000 after buying an additional 438 shares during the period. Finally, Trust Point Inc. acquired a new stake in Pacira BioSciences during the 4th quarter worth approximately $245,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PCRX has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $45.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Monday, March 4th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Thursday, February 8th. Royal Bank of Canada decreased their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Finally, JPMorgan Chase & Co. assumed coverage on shares of Pacira BioSciences in a research note on Thursday, March 7th. They set an “overweight” rating and a $45.00 price target for the company. Eleven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $49.50.

Insider Activity at Pacira BioSciences

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of Pacira BioSciences stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at $677,086.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of Pacira BioSciences stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at $677,086.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gary W. Pace sold 1,066 shares of Pacira BioSciences stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is owned by company insiders.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $25.90 on Thursday. Pacira BioSciences, Inc. has a 1-year low of $25.74 and a 1-year high of $48.60. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $28.85 and a 200 day simple moving average of $29.71. The stock has a market capitalization of $1.20 billion, a PE ratio of 31.98 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, meeting the consensus estimate of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The business had revenue of $181.24 million during the quarter, compared to analysts’ expectations of $180.60 million. On average, research analysts expect that Pacira BioSciences, Inc. will post 2.18 EPS for the current fiscal year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.